查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1318859

缓释性注射剂市场：按剂量、给药途径和最终用户 - 2023-2030 年全球预测

Sustained Release Injectables Market by Dosage, Route of Administration, End-User - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年全球缓释性注射剂市场规模将达215,686万美元，复合年增长率为6.88%，预计2030年将达345288万美元。

FPNV定位矩阵

FPNV定位矩阵对于评估全球缓释性注射剂市场至关重要。透过检查业务策略和产品满意度的关键指标，我们对供应商进行全面评估，使您能够根据您的特定需求做出明智的资讯。这种进阶分析将供应商分为四个像限，并取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市占率分析

市场占有率分析可以深入了解供应商在特定市场领域的当前地位。比较供应商对总收入、基本客群和其他关键指标的贡献，可以帮助公司更好地了解他们在争夺市场份额时的表现以及面临的情况。该分析还揭示了特定行业的竞争程度、累积和合併的优势以及研究基准年的合併特征。

本报告提供了以下几点见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开发：提供有关利润丰厚的新兴市场的详细资讯，并分析其在成熟市场的渗透率。

3. 市场多元化：提供有关新产品发布、未开发领域、最新发展和投资的详细资讯。

4.市场趋势：全面了解COVID-19、俄罗斯-乌克兰衝突和高通膨的累积影响。

5.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、法规状况、专利状况、製造能力等进行综合评估。

6. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告回答了以下问题：

1.全球缓释性注射剂市场规模及预测为何？

2.在预测期内，COVID-19 对全球缓释性注射剂市场的阻碍因素与影响为何？

3. 在预测期内，全球缓释性注射剂市场需要投资哪些产品/细分市场/应用/领域？

4.全球缓释性注射剂市场的竞争策略为何？

5. 全球缓释性注射剂市场的技术趋势和法律规范是什么？

6.全球缓释性注射剂市场主要厂商的市占率为何？

7. 哪些型态和策略性措施被认为适合进入全球缓释性注射剂市场？

目录

第1章前言

第2章调查方法

第3章执行摘要

第4章市场概况

第5章市场洞察

  • 市场动态
    • 促进因素
      • 不当的生活习惯增加导致主要慢性病盛行率上升
      • 儿童和老年人对缓释性剂的需求不断增加
      • 注射製剂比口服製剂有更好的生物利用度
    • 抑制因素
      • 填充过程中的流变变化、长期储存过程中的不稳定、释放速率不可调节
    • 机会
      • 奈米技术、微型化和稳定化製程等技术进步
      • 天然和合成可生物降解材料简介
    • 任务
      • 药品价格高且缺乏熟练的专业人员
  • 市场趋势
  • COVID-19 的累积影响
  • 俄罗斯-乌克兰衝突的累积影响
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范
  • 客户客製化

第6章缓释性注射剂市场（按剂量）

  • 原位形成製剂
  • 原位形成凝胶系统
  • 原位形成微粒系统
  • 脂质体
  • 微胶囊
  • 微球
  • 高分子奈米微胞

第7章缓释性注射剂市场：依给药途径

  • 动脉之间
  • 心内的
  • 皮内
  • 肌肉注射
  • 静脉
  • 皮下的

第8章缓释性注射剂市场：依最终用户分类

  • 诊断实验室
  • 医院
  • 专科诊所

第9章美洲缓释性注射剂市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太缓释性注射剂市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第11章欧洲、中东和非洲缓释性注射剂市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第12章竞争形势

  • FPNV定位矩阵
  • 市占率分析：主要企业
  • 竞争情境分析：主要企业

第13章上市公司名单

第14章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-43078BB92C97

The Global Sustained Release Injectables Market is forecasted to grow significantly, with a projected USD 2,156.86 million in 2023 at a CAGR of 6.88% and expected to reach a staggering USD 3,452.88 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Sustained Release Injectables Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Sustained Release Injectables Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Dosage, market is studied across In Situ Forming Formulations, In Situ Forming Gel System, In Situ Forming Microparticle Systems, Liposome, Microcapsule, Microsphere, and Polymeric Micelles. The Polymeric Micelles is projected to witness significant market share during forecast period.

Based on Route of Administration, market is studied across Interarterial, Intracardiac, Intradermal, Intramuscular, Intravenous, and Subcutaneous. The Intracardiac is projected to witness significant market share during forecast period.

Based on End-User, market is studied across Diagnostic Laboratories, Hospitals, and Specialty Clinics. The Hospitals is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.74% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Sustained Release Injectables Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Sustained Release Injectables Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Sustained Release Injectables Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Sustained Release Injectables Market?

4. What is the competitive strategic window for opportunities in the Global Sustained Release Injectables Market?

5. What are the technology trends and regulatory frameworks in the Global Sustained Release Injectables Market?

6. What is the market share of the leading vendors in the Global Sustained Release Injectables Market?

7. What modes and strategic moves are considered suitable for entering the Global Sustained Release Injectables Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Sustained Release Injectables Market, by Dosage, 2022 vs 2030
  • 4.3. Sustained Release Injectables Market, by Route of Administration, 2022 vs 2030
  • 4.4. Sustained Release Injectables Market, by End-User, 2022 vs 2030
  • 4.5. Sustained Release Injectables Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of major chronic diseases due to increasing adoption of poor lifestyle habits
      • 5.1.1.2. Rise in demand for paediatric and geriatric sustained release injectables
      • 5.1.1.3. Injectable preparations have a better bioavailability than oral preparations
    • 5.1.2. Restraints
      • 5.1.2.1. Rheological changes during filling, instability on long-term storage and nonadjustable release rate
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancement in technology such as nanotechnology, micronation, and stabilization process
      • 5.1.3.2. Introduction of natural and chemosynthetic biodegradable materials
    • 5.1.4. Challenges
      • 5.1.4.1. High cost of drugs and lack of skilled professionals
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Sustained Release Injectables Market, by Dosage

  • 6.1. Introduction
  • 6.2. In Situ Forming Formulations
  • 6.3. In Situ Forming Gel System
  • 6.4. In Situ Forming Microparticle Systems
  • 6.5. Liposome
  • 6.6. Microcapsule
  • 6.7. Microsphere
  • 6.8. Polymeric Micelles

7. Sustained Release Injectables Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Interarterial
  • 7.3. Intracardiac
  • 7.4. Intradermal
  • 7.5. Intramuscular
  • 7.6. Intravenous
  • 7.7. Subcutaneous

8. Sustained Release Injectables Market, by End-User

  • 8.1. Introduction
  • 8.2. Diagnostic Laboratories
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Americas Sustained Release Injectables Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Sustained Release Injectables Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Sustained Release Injectables Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. SUSTAINED RELEASE INJECTABLES MARKET RESEARCH PROCESS
  • FIGURE 2. SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2022 VS 2030
  • FIGURE 3. SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2022 VS 2030 (%)
  • FIGURE 5. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2030 (%)
  • FIGURE 6. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
  • FIGURE 7. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 8. SUSTAINED RELEASE INJECTABLES MARKET DYNAMICS
  • FIGURE 9. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. SUSTAINED RELEASE INJECTABLES MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 17. SUSTAINED RELEASE INJECTABLES MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. SUSTAINED RELEASE INJECTABLES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 5. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY IN SITU FORMING FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY IN SITU FORMING GEL SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY IN SITU FORMING MICROPARTICLE SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY LIPOSOME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY MICROCAPSULE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY MICROSPHERE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMERIC MICELLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 13. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTERARTERIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTRACARDIAC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. SUSTAINED RELEASE INJECTABLES MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 151. SUSTAINED RELEASE INJECTABLES MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 152. SUSTAINED RELEASE INJECTABLES MARKET LICENSE & PRICING